Jiangsu Recbio Technology Co., Ltd. (RECBIO-B) has filed its Monthly Return for Equity Issuer for the period ended 31 August 2026, confirming that both authorised and issued share capital remained unchanged during the month.
Authorised / registered share capital • Total authorised share capital stood at 626.08 million shares, each with a par value of RMB 1. • Composition: 167.98 million unlisted domestic shares and 458.09 million H-shares listed on the Hong Kong Stock Exchange.
Issued shares and treasury shares • Issued share capital was unchanged at 626.08 million shares. • No treasury shares were held or cancelled, and no new shares were issued. • The H-share component remained at 458.09 million shares; domestic shares totalled 167.98 million.
Capital-raising instruments • The company reported no outstanding or newly issued share options, warrants, convertible securities, or other equity-linked instruments.
Public float compliance • RECBIO-B confirmed adherence to the Main Board’s minimum public float requirement of 25% of its issued H-shares.
Governance affirmation • Director Liu Yong certified that all regulatory and filing obligations under Hong Kong listing rules and relevant legislation have been fully met.
With no alterations to share capital or equity-linked instruments and continued compliance with public float rules, RECBIO-B’s capital structure remains stable heading into September 2026.
Comments